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ABSTRACT
Patients suffering from pancreatic
neuroendocrine tumors (pNETs) are now
candidates to receive novel approved drugs that
have demonstrated benefit in disease control rate
and delay the time taken for tumor progression in
Phase III clinical trials; for example, sunitinib,
everolimus and lanreotide. Though pNETs
represent a rare and heterogeneous disease,
recent approaches are being taken to better
understand the molecular pathways involved in
carcinogenesis. Consequently, new treatment
strategies are now available and others still under
investigation show promising results. However,
some questions around how to approach patients
with pNETs are still unresolved, such as what the
best sequence of treatments we can offer to each of
our patients in the clinic at any time of their
disease would be. Therapeutic decisions are, at the
moment, guided by clinical judgment, based on
different parameters coming from retrospective
analysis and non-randomized clinical trials.
However, advances in genomic research would
lead to a more precise approach using therapeutic
targets that would also allow the development of
new agents, prognostic or predictive biomarkers
and a better understanding of resistance
mechanisms. The following article is a
comprehensive review of the approved and
investigational drugs in pNET, and highlights the
current concerns about treatment sequencing, but
also provides an update of some of the present and
future efforts for an improvement in the
therapeutic algorithm of the disease.
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INTRODUCTION
A wide spectrum of disease is observed in
pancreatic neuroendocrine tumors (pNETs);
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pNETs make up 3% of primary pancreatic
malignancies and 12% of all
gastroenteropancreatic neuroendocrine tumors
(GEP NETs) [1]. Five-year overall survival (OS)
rates range between 7% and 75% for patients
with high and low-grade tumors, respectively [2].
Goals of therapy for pNETs include not only the
prolongation of life, but also the improvement of
disease-related symptoms, and control of burden
of disease and quality of life.
Based on current molecular understanding,
several therapies have demonstrated efficacy in
pNETs, and novel drugs are still currently being
investigated [3]. Treatment sequencing in these
tumors is a novel concept, and has arisen from
the availability of new, different and effective
therapeutic agents. However, the correct place
of those therapies within the treatment
algorithm at each time of disease progression
to achieve maximum impact in OS is still a
matter of debate. Clinicians guide their
decisions based on different parameters, but
accurate biomarkers and information about
sequencing coming from clinical trials are still
lacking, and the wide spectrum of clinical
behaviors in pNETs brings challenges in
selecting the best treatment and monitoring
response. Therefore, a multidisciplinary
approach from expert physicians is essential in
this particular group of patients belonging to a
rare and complex disease [4].
AN OVERVIEW OF PNETS
pNETs represent both a heterogeneous and a
rare group of tumors with low frequency (0.32
diagnosed cases per 100,000 population per
year) [5]. However, this figure has been
increasing over recent years, as reported in a
Japanese survey which showed an estimated
prevalence of 2.69 per 100,000 in 2010, which
corresponded to an increase of 1.2 times the
number of patients with pNETs receiving
oncological treatment compared to 2005 [6].
Improvement in diagnostic tools, increase in
interest among physicians for the performance
of particular radiological and nuclear images,
the acquisition of adequate tumor samples, and
detailed pathological information have lead to
very accurate classification of NETs and,
consequently, to a precise therapeutic strategy.
The diagnosis of pNETs is based on clinical
symptoms, specific hormonal markers,
radiological or endoscopic images, and
pathological information. Different
classifications for pNETs according to different
issues have been proposed. About 90% of pNETs
are functional and some are able to release
peptides that are responsible for different
hormonal syndromes [4]. Histological findings
have been proposed to correlate with prognosis
[7]. Thus, the last updated classification from the
World Health Organization (WHO) divided NETs
into two different categories: (1) well-
differentiated (WD)-NETs G1 (mitotic count
\2 9 10 high power field [HPF] and Ki67 index
B2%) and G2 (mitotic count 2–20 9 10 HPF and
Ki67 index 3–20); and (2) poorly differentiated
(PD)-neuroendocrine carcinomas (NECs) G3
(mitotic count[20 9 10 HPF and Ki67[20) [8].
Recent advances in nuclear medicine using
radiolabelled somatostatin analog (SSA) agents
overcome challenging issues in the diagnostic
and therapeutic assessment of NETs, such as the
development of somatostatin receptor
scintigraphy (SRS) using 111In-octreotide [9].
Indeed, novel radiopharmaceuticals for use in
positron emission tomography (PET) imaging
with better resolution have shown to improve
the limitations of the previous methods in
diagnosis (e.g., location of primary tumor or
recurrent disease and identification of cellular
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populations), staging, treatment approach (in
loco-regionally confined or intermediate grade
tumors), treatment monitoring and prediction of
response [10]. A precise histological report is
essential in NETs and, in G2-NETs and high grade
NECs, the question of whether all patients in
each group should be treated the same way is now
under debate. Recent findings highlight the
heterogeneity within the group of patients
harboring high-grade NECs as well as the need
for predictive and prognostic factors to select the
optimal treatment [11]. Should we consider
different treatment schedules according to
differentiation and Ki67? Some controversial
aspects include the consideration of different
subtypes, such as a group of differentiated, but
highly proliferative tumors (Ki67 20–50%; NET
Grade 3) and a group of true PD-NECs
(Ki67[50–55%; NEC) [12]. These novel groups
are not well stratified or represented in earlier
clinical trials, and thus definitive conclusions are
more difficult to suggest according to a specific
group of patients. Current and ongoing clinical
trials are trying to solve this problem by focusing
the studies in more homogeneous subgroups of
patients and stratifying them properly.
Prognosis in pNETs is related to the clinical
stage at diagnosis [1]. The European
Neuroendocrine Tumor Society (ENETS) TNM
staging system describes a 5-year OS rate for stage
I, II, III and IV of 100%, 88%, 85% and 57%,
respectively [1]. The American Joint Committee
on Cancer (AJCC) classification establishes a
5-year OS rate for stage I, II, III and IV of 92%,
84%, 81% and 57%, respectively [1].
CURRENT TREATMENTS FOR PNETS
Despite the recent availability of a number of
drugs for the treatment of pNETs and the
extensive field of current research, there are
some unresolved issues in the management of
tumors that are expected to be elucidated in the
near future.
Treatment algorithm for the best treatment
approach is still under debate; patients with
NETs should be treated with all the available
regimens for their precise classification to
achieve the maximum prolongation in
survival and maintenance of quality of life,
together with adequate symptom control.
Treatment decisions are based on tumor
characteristics (e.g., differentiation, Ki67,
mitotic rate), stage, clinical course, tumor-
related symptoms, tumor secretory symptoms,
rate of progression, number of affected organs,
disease burden, functioning, findings from
somatostatin receptors (SSTRs), European
Cooperative Oncology Group (ECOG)
performance status, comorbidities, and
concomitant medication. In fact, there is a
lack of data comparing the activity of different
treatment strategies, and final decisions are
based on personal experience and expert
consensus statements [2]. In this context,
different questions are still undefined, such as
the best treatment sequence and whether all
patients may benefit from all available drugs;
the reliable prognostic and predictive
biomarkers to guide our treatment decisions;
whether combination strategies improve
efficacy over sequential monotherapy regimens
in a safe manner or by increasing efficacy by
adding cytotoxic agents to targeted agents to
improve the limited response rates of available
drugs; the duration of treatment agents; or the
real OS benefit of currently used drugs.
Several mechanisms of resistance have been
suggested relating to SSAs, such as
desensitization or downregulation of SSTRs on
the cell surface of tumor cells or its
internalization after a prolonged exposure to
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an agonist; different SSTR subtype expression
patterns; the development of functioning
mutation forms of SSTR; the generation of
antibodies against SSA; or changes in
regulatory proteins (amphyphysin IIb) that are
involved in SSTR stabilization [13]. Different
strategies proposed to overcome resistance to
SSA include administration of SSAs in a high-
dose or short-schedule manner; the sequential
treatment of both available SSAs (octreotide/
lanreotide); and the development of chimeric
SST/dopamine receptor [DR] molecules [14] or
targeted agents to multiple SSTR, such as
pasireotide [15]. However, none of those
strategies have enough strength to allow
definitive conclusions. The Cooperate-2 Phase
II trial presented at ENETS 2015 did not show a
benefit in the primary endpoint in the group of
patients treated with everolimus and pasireotide
compared with single-agent everolimus
(median progression-free survival [PFS] 16.6
versus 16.8 months, hazard ratio [HR] 0.99,
95%; CI 0.64–1.54; p = 0.488) [16].
The beneficial role of antiangiogenic agents
in pNETs is undeniable. However, resistance
mechanisms have also been identified in
patients treated with targeted therapies based
on the activation of alternative pathways [17]
by the presence of other angiogenic factors,
including vascular endothelial growth factor
(VEGF)-independent vessel growth,
inflammatory cells releasing cytokines with
proangiogenic effect and protecting cells from
hypoxia, pericyte coverage, and enhancing
invasiveness [18]. Different ways have been
proposed to overcome those resistance
mechanisms: optimizing the dose of the drug,
switching to an alternative VEGF therapy,
switching to a drug with a different
mechanism of action, or using a combination
strategy [19]. Mammalian target of rapamycin
(mTOR) inhibitors’ evasive resistance involves
the activation of alternative pathways or
feedback loops (RAS/RAF/Erk pathway),
dysregulation of downstream pathways (loss of
4E-BP1 inhibition, eIF4E activation, loss of
function of PP2A, p27 levels, cyclin D1
expression) and promotion of autophagy [18].
Potential mechanisms to overcome resistance to
mTOR inhibitors are: dual blockade of mTOR
complexes 1 and 2 (mTORC1 and mTORC2),
combination therapies with an mTOR inhibitor
and a second agent that blocks upstream kinases
(protein kinase B [AKT] or phosphatidylinositol
3-kinase [PI3 K]) or receptors (insulin growth
factor receptor [IGFR]), mTOR/epidermal
growth factor receptor [EGFR] dual inhibition
[rapamycin/erlotinib] [20], or switch to an agent
with a different mechanism of action [21].
Initial trials in NETs showed a trend to a
better outcome for patients with pNETs treated
with cytotoxic drugs over patients with
carcinoid tumors [22]. Alkylating agents were
investigated early in the discovery of NETs, and
streptozocin (STZ) was the first drug approved
by the Food and Drug Administration (FDA) in
1976. Combination therapy with doxorubicin
and fluorouracil or single-agent dacarbazine
obtained promising overall response rate
(ORR) results of up to 70% in several clinical
trials [23, 24] (Table 1). However, the outcome
criteria used in earlier trials, based on non-
radiographic response criteria, are not
consistent and comparable with those we rely
on today. A more recent trial assessing tumor
response with modern criteria showed an ORR
of 39% with STZ-based chemotherapy [25] and
an international survey described that this
treatment strategy is broadly administered in
patients with NETs [26].
Moreover, three targeted agents (Table 1)
have been recently approved for the treatment
of patients with advanced and progressive
pNETs. Interest in antiangiogenic agents
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started with the discovery of NETs with high
vasculature, and good results in efficacy have
been obtained from a Phase I dose escalation
study with sunitinib for advanced malignancies
in this subgroup of patients [27]. The Phase II
trial included 66 patients with pNETs, and
showed an ORR of 16.7% and median time to
progression (TTP) of 7.7 months [28]. Finally,
the Phase III placebo-controlled trial was
conducted, but terminated early due to safety
measures relating to an increase in serious
adverse events, disease progression and deaths
observed in the placebo group [29]. A total of
171 patients were finally randomized to
sunitinib versus placebo (1:1) and the benefit
in PFS was almost 6 months for the patients in
the experimental group (median PFS
11.4 months versus 5.4 months; HR 0.42; 95%
CI 0.26–0.66, p\0.001).
The mTOR pathway that is involved in the
regulatory functions within the tumor and
tumor microenvironment also plays an
important role in the development of NETs
due to gene mutations, such as phosphatase and
tensin homolog (PTEN), tuberous sclerosis 2
(TSC2) and PI3 K, catalytic, alpha polypeptide
(PI3KCA), or activation of insulin growth factor
1 (IGF1) [30]. The approval of everolimus for the
treatment of pNETs following the results of its
pivotal Phase III trial was based on the benefit
observed in two Phase II previous studies. The
first study included 60 patients with naı¨ve or
previously treated WD-NETs (N = 30 patients
with pNET) who received treatment with
everolimus 5 mg or 10 mg daily and octreotide
long-acting repeatable (octreotide LAR) 30 mg
monthly [31]. The ORR in pNETs was 27%, and
6- and 12-month PFSs were 73% and 48%,
respectively. The second study was the
RADIANT-1 that was conducted to assess the
benefit of everolimus 10 mg once daily with or
without octreotide LAR in 160 pretreated
patients with progressive WD-pNETs [32]. The
data were consistent with previous trials:
median PFS and OS were 8.5 and 24.9 months
for everolimus, respectively. For patients treated
with everolimus plus ocreotide LAR, PFS was
15.2 months and OS was not reached. These
data showed a trend towards a better outcome
with both treatments together. The Phase III
RADIANT 3 clinical trial assessed the benefit of
everolimus as first line therapy in pNETs; 410
patients were randomized to receive everolimus
10 mg or placebo every 24 h [33]. The first
analysis showed a benefit in the primary
endpoint with a median PFS of 11.0 months in
the everolimus group and 4.6 months in the
placebo group (HR 0.35; 95% CI 0.27–0.45,
p\0.001). The updated outcome results that
included the data from the open-label
extension phase were presented at the
European Society of Medical Oncology (ESMO)
2014 Congress; everolimus obtained 6.3-month
longer median OS compared with placebo
(44.0 months versus 37.68 months; HR 0.94;
95% CI 0.73–1.20, p = 0.3) [34].
The antiproliferative effect of SSAs in
addition to tumor-related symptom relief has
been validated in prospective Phase III trials
[14]. The PROMID trial firstly demonstrated this
benefit by randomizing 85 patients with grade 1
midgut NETs to octreotide LAR 30 mg versus
placebo [35]. However, some questions
remained unresolved, such as the role of SSAs
in patients with non-midgut and grade 2
tumors, larger hepatic tumor burden and non-
progressive disease. The CLARINET trial was
conducted including these subgroups of
patients, among others [36]. This Phase III trial
included 204 patients with non-functioning
NETs (44% pancreas, 30% grade 2 Ki67 B10%,
and 33% with liver tumor burden [25%) that
were randomized to lanreotide autogel 120 mg
or placebo monthly. For the whole population,
18 Rare Cancers Ther (2015) 3:13–33
the median PFS was not reached for the
lanreotide group, and was 18.0 months for the
placebo group (HR 0.47; 95% CI 0.30–0.73,
p\0.001). In the subgroup analysis, the median
PFS in patients with pNETs was not reached for
the experimental arm and was 12.1 months for
the placebo arm (HR 0.58; 95% CI 0.32–1.04,
p = 0.0637). The results from the open-label
extension CLARINET study showed a median
PFS of 32.8 months [37].
PROGRESS IN PNET TREATMENT
Ongoing research around pNETs has showed
promising results with novel agents acting
through different targets. Although this is a
vast improvement, the search for reliable
biomarkers and further understanding is still
lacking. The anti-apoptotic protein survivin was
suggested as a possible predictive biomarker to
the dual-targeted therapy, rapamycin and
erlotinib [20]. The involvement of the VEGFR2
pathway in NETs was suggested by the
PAZONET researchers based on tumor
expression and soluble VEGFR2 (sVEGFR2)
detection [40, 41]. Decrease in soluble VEGFR2
(sVEGFR2) levels was associated with better PFS
compared with patients whose sVEGFR2 levels
increased: 12.6 versus 9.1 months, respectively
(p = 0.067). Other potential predictive
biomarkers, such as sVEGFR3, stromal cell-
derived factor 1 alpha (SDF1-a), endothelial
progenitors or circulating endothelial cells, are
still not validated in pNETs [40]. Sensitivity to
temozolomide, an inductor of DNA
methylation at the O6 position of guanine has
been related to low levels of O6-methylguanine
DNA methyltransferase (MGMT), an enzyme
related to DNA repair [41]. There are two trials
that assessed the association of MGMT
expression and response to temozolomide-
based therapy (N = 21 and N = 53), which
showed a median PFS for the group of patients
with intact MGMT of 9.25 and 7.5 months,
respectively, compared with the group of
patients harboring tumors deficient of MGMT
(19 and 20 months, respectively) [41, 42].
However, those data are not sufficient to
consider MGMT status as an independent
predictive factor, as prospective data are
required to validate it. At the moment, target
expression in NETs is not good enough to
predict response; in fact, there is currently no
definitive biomarker that could guide our
therapeutic decisions in the clinic, not only
because of its limited accuracy in sensitivity and
specificity, such as with cromogranin A, but also
for the technical efforts and costs required for
the general applicability of the potential
biomarkers proposed at the moment [30].
Some of the following drugs and treatment
strategies are currently being investigated, and
study results look promising for clinicians to be
able to place these agents into treatment
algorithms for patients with pNETs.
PEPTIDE RECEPTOR RADIONUCLIDE
THERAPY (PRRT)
The benefit of nuclear medicine in diagnosis
and treatment of NETs is also currently being
investigated in tumors of pancreatic origin,
although the real value of peptide receptor
radionuclide therapy (PRRT) in the different
NET types and in which line should it




outcome results with substantial responses to
therapy (ORR = 28–37%) and prolonged disease
control, even following the last dose of
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treatment [44]. The least benefit was obtained in
patients with poor performance status,
significant weight loss, high hepatic tumor
burden or bone metastases [45]. According to
the low mitotic rate in patients with WD and
low-grade pNETs, this treatment strategy can be
considered early on in disease progression based
on clinical symptoms, serum markers or
radiological images to achieve a long-term
outcome. However, hematologic adverse
events must be taken into account to avoid
cumulative toxicity that could limit subsequent
treatment lines. In this sense, safety of
everolimus after PRRT (median time
18.7 months) was analyzed in a multicenter
retrospective study including 24 patients
[46]. The more frequent grade 3/4 adverse
events were hyperglycemia (12.5%),
thrombocytopenia (8.3%) and fatigue (8.3%).
However, data from a compassionate use
program showed that patients treated with
everolimus after PRRT and chemotherapy had
a significant increased risk of toxicity and
treatment discontinuation. Grade 3–4 adverse
events were described in 87% of patients [47].
ANTIANGIOGENICS
As we know, NETs are vascularized tumors with
overexpression of VEGF/VEGFR; therefore, new
antiangiogenic agents, such as sunitinib among
others, are currently being investigated. In a
Phase I clinical trial, pazopanib achieved a
partial response in a patient with a NET [48].
The mechanism of action of pazopanib and the
different selectivity and interaction pattern to
other tyrosine kinase inhibitors (TKIs) [49] has
been investigated in different clinical settings in
Phase II non-randomized clinical trials with and
without combination with SSAs, including the
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introduce the sequential strategy concept with
targeted therapies [50–52].
Bevacizumab, a monoclonal antibody
targeting VEGF, has been under research in
NETs in combination with other agents with
activity in pNETs, such as temozolamide and
fluoropirimidines/STZ with or without
oxaliplatin and temsirolimus or sorafenib [55–
59]. The trials achieved an ORR of 9–41% and
median PFS of 11.0–23.7 months. However,
there are limitations to these studies, such as
small sample size, potential biases in patient
selection, different concurrent use of octreotide
and the absence of knowledge of the real
contribution of bevacizumab in the control of
disease. Toxicities in some trials required a dose
reduction in 63–80% of patients [57–59],
though the majority of these were easily
manageable.
FIBROBLAST GROWTH FACTOR




The inhibition of the complex fibroblast growth
factor (FGF) family has been suggested as a
potential strategy to overcome one of the
mechanisms of resistance to VEGF/VEGFR
inhibitors by FGF activation [60]. Brivanib is a
first-in-class dual VEGFR/FGFR TKI that is
currently being investigated in hepatocellular
and colon cancer. Efficacy of brivanib was
investigated in the RIP1-TAG2 mouse model as
first- or second-line treatment after single
VEGFR2 inhibition (DC101), FGF inhibition
(FGF-trap) or VEGFR/PDGFR/RAF inhibition
(sorafenib). Brivanib shows activity after
failure of first-line VEGFR inhibition, but
mainly acts as first-line treatment because of a
possible partial blockade of the adaptive
mechanisms of evasive resistance [61].
ENDOTHELIAL GROWTH FACTOR
RECEPTOR (EGFR) INHIBITORS
Endothelial growth factor receptor (EGFR)
signaling is involved in tumor progression and
survival, and has been shown to be a
therapeutic target in different tumors [62].
Preclinical data from erlotinib in the Rip1-
Tag2 mouse model of pNETs showed
antitumor activity of growth and angiogenesis
[62]. Moreover, concurrent phosphorylation of
EGFR and AKT (and S6 ribosomal protein) was
described during progression, showing a
contribution to PI3 K pathway promotion due
to EGFR activation [20]. Based on the
concurrent activation of mitogen-activated
protein kinase (MAPK) and PI3 K pathways,
preclinical research has been conducted to
elucidate the potential benefit of dual
therapeutic targeting: e.g., rapamycin and
erlotinib. Findings showed promising efficacy
results overcoming adaptive resistance of single
mTOR inhibitors by the loss of the upstream
feedback loop and consequent hyperactivation
of AKT [20]. The role of EGFR inhibitors has
been investigated in Phase II clinical trials with
gefitinib showing activity [63]. Furthermore,
there is a currently ongoing Phase II trial
investigating patients with low-grade NETs
treated with combination therapy of
everolimus and erlotinib (clinicaltrials.gov
identifier: NCT00843531) (Table 3).
ALKYLATING AGENTS
Some cytotoxic agents have been investigated
in pNETs due to the cumulative evidence
showing higher sensitivity of this subtype of
24 Rare Cancers Ther (2015) 3:13–33







Phase I NET SNX-5422 mesylate (Hsp90 inhibitor)
? everolimus
DLT NCT02063958
Phase Ib NET Sulfatinib Safety NCT02267967









NET/ACC TKM-080301 (small interfering RNA) DLT
MTD
NCT01262235
Phase II pNET Dovitinib 6-month PFS NCT02108782







NET Everolimus ? erlotinib ORR NCT00843531
Phase II Non-
randomized
NET Geﬁtinib 6-month PFS NCT00075439
Phase II Non-
randomized







GEP-NET Lanreotide autogel ? temozolamide 6-month DCR NCT02231762
Phase II (NORDIC)
Non-randomized

















pNET 177Lutetium-octreotate versus sunitinib 12-month PFS NCT02230176
Phase II (CALGB
80701) Randomized






Lanreotide autogel versus placebo as
maintenance therapy after response to ﬁrst
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NET to chemotherapy. Temozolomide is an
orally available alkylating agent developed as a
less toxic drug compared with dacarbazine
(DTIC) that showed activity earlier in NETs
[24]. The potential role of temozolamide in
NETs is based on its capacity for DNA
methylation at the O6 position of guanine.
Therefore, this agent has been, and is still
currently, being studied as a single agent or in
combination with a number of different drugs
for the treatment of NETs (Tables 2, 3). At the
moment, studies investigating temozolomide in
combination with thalidomide, based on its
antiangiogenic activity against VEGFR and basic
FGF (bFGF), found a significant number of
infectious complications [64], but in
combination with capecitabine (CAPTEM),
based on the synergistic activity with
temozolomide observed in preclinical research,
have demonstrated clinical efficacy and a good
safety profile [41]. The cytotoxic effect of
alkylating agents of tumor cells with
prolonged G0 phase, such as those from WD-
NETs, is delivered in a time-dependent manner
in combination with a continuous exposure to
an antimetabolite agent (fluorouracil [5-FU] or
capecitabine) or by the MGMT cell depletion
conducted by fluoropyrimidines [65] which
represent some of the possible synergistic
mechanisms.
COMBINATION THERAPIES
Unfortunately, patients finally progress under
initial systemic treatment and subsequent
therapies are required as currently there are no
agents able to cure the disease. Therefore,
current research in NETs also focuses on the
mechanisms of intrinsic or acquired resistance
that interfere at some point of the disease in the
majority of patients. Two major strategies are
suggested to overcome resistance in pNETs,
such as the combination of targeted therapies
with similar mechanisms of action
(antiangiogenic approach, such as FGF/VEGF
inhibitor [63]), different mechanisms of action
(such as temsirolimus or everolimus, and
bevacizumab [57]; clinicaltrials.gov identifier:
NCT01229943), or by multiple pathway










pNET Everolimus) STZ ? 5-FU
STZ ? 5-FU) Everolimus
Second PFS NCT02246127
Phase III Randomized pNET Temozolomide ± capecitabine PFS NCT01824875
CT cytotoxic chemotherapy, CTC enumeration of CTC, DCR disease control rate, DLT dose-limiting toxicities, GEP-
NET gastroenteropancreatic neuroendocrine tumors, Hsp90 heat shock protein 90, LAR long-acting repeatable, MTD
maximum tolerated dose, NET neuroendocrine tumor, ORR objective response rate, OS overall survival, PD markers
pharmacodynamics markers, PFS progression-free survival, PK parameters pharmacokinetic parameters, pNET pancreatic
neuroendocrine tumor, Second PFS PFS of course 1 ? interval between treatments ? PFS of course 2, SSA somatostatin
analogs, STZ streptozotocin
a Clinicaltrials.gov identifer 5-FU ﬂuorouracil
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[20] or BEZ235 [66]) and by sequencing
therapies.
WHAT CAN WE EXPECT
IN THE FUTURE
FOR THE MANAGEMENT OF PNET?
We can differentiate five different approaches for
the treatment of pNETs, such as local treatments
(hepatic-directed therapies, surgery), SSAs,
PRRTs, biologically targeted agents and
cytotoxic regimens [67]. The selection of the
appropriate sequential treatment results in
challenging the context of a multidisciplinary
approach that becomes essential in this new
complex scenario of pNETs.
As it would be hardly possible to conduct a
clinical trial for every sequence including all
available drugs, surgical and embolization
approaches and combination or ‘‘watch and
wait’’ strategies, the correct patient
stratification based on the improvement of the
molecular biology information would help to
choose the best treatment option at a precise
time of the disease. Understanding molecular
behavior based on genetic aberrations resulting
in actionable signaling pathways would in
decision making.
What have we learnt from the available
clinical trials or retrospective series?
Considering that most of our treatment
decisions in pNETs are based on clinical
discernment [67], some guidance can be
obtained from clinical studies. Preferential use
of SSAs as first-line therapy can be considered in
patients harboring WD-pNETs (Ki67\10%) and
stable or early and slow progressive tumors.
Sunitinib and everolimus have also
demonstrated outcome benefit in this
subgroup of patients and in those with
increased tumor burden, rate of progression
and more aggressive histological findings, such
as WD-NETs (the role of everolimus in PD-NETs
is under research) and in patients showing
contraindication to cytotoxic drugs [29, 30].
Whether the maintenance of SSAs beyond
progression adds outcome benefit needs to be
confirmed in larger clinical trials (this has not
yet been done due to its safety profile in
combination with other drugs). Results from
the PAZONET trial showed benefit of pazopanib
in previously treated and targeted-agent naı¨ve
patients [68]. In patients with high burden and
symptomatic disease, the use of cytotoxic
agents for tumor shrinkage may be appropriate
as an initial approach. In fact, safety and
efficacy between targeted agents (everolimus)
and chemotherapy (5-FU ? STZ) are being
assessed in the SEQTOR trial (clinicaltrials.gov
identifier: NCT02246127) (Table 3). At the
moment, targeted agents have also shown
efficacy in previously treated patients. In the
SUN1111 trial, 35–38% of patients had received
previous treatment with SSAs and 66–72% had
received treatment with cytotoxic
chemotherapy [29]. In the RADIANT-3 trial,
about 50% of patients had received an SSA and
chemotherapy prior to everolimus [33].
However, controversial results have been
obtained after treatment with PRRT [46, 47].
Following on from the information obtained
from trials investigating SSAs, the PROMID trial
only included treatment-naı¨ve patients, and the
CLARINET trial included 16% of patients
previously treated [35, 37]. Finally, PRRT could
be considered in patients with WD-NETs with
high uptake of tumor lesions on SSTR
scintigraphy and not showing potential worse
predictive factors, such as clinical deterioration
or high tumor burden (e.g., in liver or bone).
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Treatment-related adverse events can also
influence our therapeutic decisions, as well as
taking into account patients’ comorbidities and
concomitant treatments. Cytotoxic drug
combinations, such as 5-FU, STZ and
bevacizumab, showed Grade 3–4 hypertension,
abdominal pain and thromboembolic events.
Temozolomide-based regimens showed
infectious complications due to the
immunosuppressive effect due to prolonged
exposures for more than 6 months [64] and
cumulative toxicities from the temozolomide
and thalidomide regimen, whereas 66% of
patients discontinued treatment due to
treatment-related toxicity. In the CLARINET
trial, 3% of patients suffered from serious
adverse events related to study treatment. The
most frequent Grade 3–4 adverse events in the
RADIANT-3 trial were stomatitis (7%), anemia
(6%), hyperglycemia (5%) and
thrombocytopenia (4%), and in the SUN1111
trial were neutropenia (12%), hypertension
(10%) and diarrhea and asthenia (5%) [29, 33,
37].
Treatment goals in pNETs include
improvement of survival, relief of tumor-
related symptoms, inhibition of tumor growth,
prevention of complications and maintenance
of a good quality of life. According to these
objectives, particular advantages from targeted
therapies in pNETs include prolongation of
disease control and survival with an acceptable
safety profile that allows these drugs to be
administered in a wide spectrum of the
disease. Indeed, treatment with these agents is
not associated with cumulative toxicity
following therapeutic strategies, even in
patients remaining on treatment for prolonged
periods of time. In this context, combination
strategies with 2 or 3 drugs are currently being
investigated to try to offer a clinical benefit
based on a theoretical synergy between agents
that might overcome some mechanisms of
escape without a significant increase in
adverse events (Table 3). Some examples of
these combination strategies include SSA with
sunitinib or everolimus, mTOR inhibitors
(everolimus/temsirolimus) with bevacizumab,
or everolimus with cytotoxic agents
(temozolomide). In fact, research around
temozolamide-based treatment regimens goes
further based on the promising data from
retrospective and Phase II clinical trials in
WD-NETs and as a salvage therapy in a
subgroup of PD-NECs [69–72]. Moreover,
based on the benefit observed with targeted
agents, with the aim of increasing the tumor
response rates, the combination of those drugs
with cytotoxic agents, such as temozolomide,
is currently being investigated (Tables 2, 3)
[73].
In addition to combination strategies, more
information around sequencing strategies is
required. An ongoing Phase III clinical trial,
the SEQTOR trial, would allow the assessment
of the real activity of this regimen with updated
response criteria and would help assess the right
treatment sequence for patients with pNETs,
e.g., everolimus followed by streptozotocin–
fluorouracil or vice versa (Table 3).
Finally, new agents in the treatment
paradigm of pNETs are also appearing, such as
drugs targeting death-domain associated
protein/alpha thalassemia/mental retardation
syndrome X-linked (DAXX/ATRX). Recent
findings in genomic research discovered the
role of telomere remodeling genes DAXX/ATRX
in NET carcinogenesis with a relatively high
mutation rate of 43% in WD-pNETs [30]. This
may be related to a loss of function of p53 in cell
cycle progression [74]. Consequently, ongoing
early development clinical trials are underway
to assess these agents as treatment options in
solid tumors.
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CONCLUSIONS
Treatment sequencing has emerged as a
challenging new concept considering the
number of effective novel agents that have
emerged in the last years for patients with
pNETs. Treatment decisions at any time of the
disease require enough data to determine the
optimal therapeutic strategy to ensure they are
not solely based on clinical parameters. Current
research is aimed at improving knowledge
around the molecular biology of NETs and at
assessing different sequencing or combination
strategies, including optimum patient
stratification in clinical trials that would
consequently help when making treatment
decisions.
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